HC Wainwright Reiterates Buy Rating for Gossamer Bio (NASDAQ:GOSS)

HC Wainwright restated their buy rating on shares of Gossamer Bio (NASDAQ:GOSSFree Report) in a research note published on Thursday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Gossamer Bio’s FY2029 earnings at $0.59 EPS.

Gossamer Bio Trading Up 3.1 %

Shares of GOSS stock opened at $0.99 on Thursday. The firm has a market capitalization of $225.15 million, a PE ratio of -3.11 and a beta of 1.81. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The stock has a fifty day moving average of $0.87 and a two-hundred day moving average of $0.90. Gossamer Bio has a 1 year low of $0.50 and a 1 year high of $1.60.

Gossamer Bio (NASDAQ:GOSSGet Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $9.48 million for the quarter, compared to the consensus estimate of $4.52 million. As a group, research analysts expect that Gossamer Bio will post -0.28 EPS for the current year.

Hedge Funds Weigh In On Gossamer Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Marshall Wace LLP boosted its holdings in shares of Gossamer Bio by 170.8% in the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock worth $3,002,000 after buying an additional 2,103,766 shares during the period. GSA Capital Partners LLP acquired a new position in Gossamer Bio in the 3rd quarter worth approximately $67,000. US Bancorp DE purchased a new position in Gossamer Bio during the 3rd quarter worth approximately $39,000. The Manufacturers Life Insurance Company raised its stake in Gossamer Bio by 67.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company’s stock valued at $279,000 after purchasing an additional 124,913 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of Gossamer Bio by 26.7% in the third quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock valued at $117,000 after purchasing an additional 25,000 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Recommended Stories

Analyst Recommendations for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.